Machine Learning, Artificial Intelligence, and Systems Biology: A New Way to Interrogate ’Omics Data

This Precision white paper concisely illuminates how using machine learning and artificial intelligence fused with systems biology can harness the value in rich ‘omics data to provide novel insights. These insights can lead to the development of a diagnostic to monitor disease progression or guide treatment decisions. The white paper, “Machine Learning, Artificial Intelligence, and Systems Biology,” offers insights on …

TTP Labtech

[WHITEPAPER] Multiplexed fluorescence ELISA assays on mirrorball®

Multiplexed fluorescence ELISA assays on mirrorball® Download the whitepaper courtesy of TTP Labtech Inc here > Enzyme-linked immunosorbant assays (ELISA) can be used in multiple stages of the drug discovery process to help identify and measure the cellular responses to therapeutic or toxic molecules. The most common ELISA format is the sandwich assay. Briefly, a capture antibody is immobilised onto …

Francisco Kuribreña of Landsteiner Scientific's 2015 Presentation

Landsteiner Scientific on Mexican biosimilars

We were excited to have Francisco Kuribreña, Director of New Development at Landsteiner Scientific, share his expertise on institutional experiences in preclinical evaluation of biosimilars in Mexico at last year’s World Biosimilar Congress USA. Download his presentation now > You can now download Francisco’s presentation to find out more about: The emerging Mexican economy Mexico and the pharma business The …

Doug Monroe of Kaiser Permanente's 2015 Presentation

Kaiser Permanente: the impact of biosimilars on private reimbursement

We were excited to have Doug Monroe, Project Manager of Biotechnology, Emerging Technology, and Specialty Pharmacy at Kaiser Permanente, share his expertise on the impact of biosimilars on private reimbursement strategies at the World Biosimilar Congress USA. Download his presentation now > You can now download Doug’s presentation to find out more about: The Kaiser Permanente integrated health care delivery system …

Ira Jacobs of Pfizer's 2015 Presentation

Pfizer shares their expertise on biosimilars on the horizon

Doctor Ira Jacobs is a fellowship trained surgical oncologist who is currently Pfizer’s oncology biosimilars global medical lead. Prior to Pfizer, Doctor Jacobs worked as a medical director in oncology global development at Amgen. He led clinical development programs in breast, lung, prostate, and bone cancers. Prior to transitioning into industry, Dr. Jacobs was a staff surgical oncologist. We were …

Vladimir Hanes of Amgen's 2015 Presentation

Amgen’s meaningful biosimilar development programs

We were excited to have Vladimir Hanes, Medical Director of Oncology/Biosimilars at Amgen, share his expertise on the structure, function, and the science of biosimilarity in designing meaningful biosimilar development programs at last year’s World Biosimilar Congress USA. Download his presentation now > You can now download Vladimir’s presentation to find out more about: FDA & EU definitions of biosimilars …

Andrew Hiatt of Mapp's 2015 Presentation

Mapp shares lessons learned from Ebola

We were excited to have Andrew Hiatt, CSO of Mapp, gave a keynote address titled “Lessons from Ebola – Pandemic preparedness and antibodies against infectious diseases” at last year’s Americas Antibody Congress. Download his presentation now > You can now download his presentation to find out more about: Typical symptoms of the Ebola virus disease Emerging treatments Antibody failures Neutralization …

Preview agenda announcement - Americas Antibody Congress

Announcing the release of the preview agenda – Americas Antibody Congress

The preview agenda for Americas Antibody Congress 2016 is now LIVE. Download the preview agenda here > Join us in San Diego next May for an expanded two-day event and deeper content than ever before in: Antibody Engineering Oncology Infectious Diseases ADCs/Bioconjugates Download the preview agenda here to find out more about the content on offer > That’s four full …

Biooutsource

Biosimilars have caused a revolution in the development of biologic drugs

Remsima Case Study: The importance of ADCC in assessing clinically relevant differences Authors: Dr. Daniel Galbraith, Chief Scientific Officer and Andy Upsall, Director of Technical Services – BioOutsource Ltd. The Regulatory Authorities Verdict “Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental …

Contemporary Science Insights: Next Generation Therapies

In general terms, stem cells are cells that can duplicate themselves and differentiate into cell types found in the body. However stem cells are not all equal. Embryonic stem (ES) cells can transform into any cell type found in the body and this gives rise to the term, “pluripotent” cells. Human ES cells are obtained from pre-implantation embryos, created using in …